Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 58 entries
View as:

Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT00442026 Org: User:
Start: 12/31/06 End: 05/31/10 Due: 05/31/11

Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00441922 Org: User:
Start: 01/31/03 End: 01/31/08 Due: 01/31/09

Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00429559 Org: User:
Start: 06/30/06 End: 07/31/11 Due: 07/31/12

Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01982500 Org: User:
Start: 03/31/12 End: 07/31/17 Due: 07/31/18

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00691379 Org: User:
Start: 04/30/08 End: 03/31/16 Due: 03/31/17

Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT02179567 Org: User:
Start: 03/31/10 End: 03/31/13 Due: 03/31/14

Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01399086 Org: User:
Start: 04/30/11 End: 09/30/11 Due: 09/30/12

Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

Phase: N/A Priority: Normal
NCT ID: NCT00755534 Org: User:
Start: 11/30/08 End: 11/30/08 Due: 11/30/09

Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01985841 Org: User:
Start: 10/31/11 End: 04/30/15 Due: 04/30/16

Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00424606 Org: User:
Start: 06/30/01 End: 08/31/13 Due: 08/31/14

Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas

Phase: N/A Priority: Normal
NCT ID: NCT00750386 Org: User:
Start: 01/31/08 End: 03/31/11 Due: 03/31/12

Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02251951 Org: User:
Start: 09/30/12 End: 06/30/15 Due: 06/30/16

Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT00620971 Org: User:
Start: 01/31/08 End: 04/30/10 Due: 04/30/11

NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy"

Phase: N/A Priority: Normal
NCT ID: NCT03771404 Org: User:
Start: 01/05/18 End: 12/01/21 Due: 12/01/22

Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00755170 Org: User:
Start: 11/30/08 End: 10/31/16 Due: 10/31/17

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Phase: N/A Priority: Normal
NCT ID: NCT00615758 Org: User:
Start: 10/31/06 End: 11/30/09 Due: 11/30/10

Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01120158 Org: User:
Start: 09/30/09 End: 01/31/17 Due: 01/31/18

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00453635 Org: User:
Start: 12/31/03 End: 11/30/08 Due: 11/30/09

Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00431106 Org: User:
Start: 04/30/02 End: 01/31/09 Due: 01/31/10

Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00431613 Org: User:
Start: 03/31/06 End: 02/28/09 Due: 02/28/10

Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

Phase: N/A Priority: Normal
NCT ID: NCT00469443 Org: User:
Start: 12/31/06 End: 02/28/10 Due: 02/28/11

Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01978977 Org: User:
Start: 07/31/11 End: 03/31/15 Due: 03/31/16

Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01716546 Org: User:
Start: 07/31/11 End: 01/31/15 Due: 01/31/16

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00431080 Org: User:
Start: 08/31/04 End: 10/31/07 Due: 10/31/08

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00440622 Org: User:
Start: 04/30/03 End: 11/30/08 Due: 11/30/09